Purchase Order 75F40123P00391
Award Date 9/11/23
Potential Completion Date 10/17/23
Potential Value $25K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Hudson, NH 03051, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $97,222.00 firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Integra Biosciences Corp., a foreign-owned, for-profit manufacturer of laboratory equipment. The contract is for the delivery of MediaJet base units and MediaClave base units with accessories. Integra Biosciences Corp. is a registered vendor in the System for Award Management (SAM) and has an extensive history of federal contract awards from various agencies, including the NIH, CDC, USDA,...
- Integra Biosciences Corp., a foreign-owned manufacturer of advanced laboratory equipment headquartered in Hudson, New Hampshire, was awarded a $18,666.15 firm fixed-price purchase order for a liquid handling station by the Pacific West Area, a civilian component of a federal agency. The contract, designated as a Total Small Business set-aside, was awarded on September 23, 2019, with an ultimate completion date of November 1, 2019. The work will be performed at the contractor's facility in...
- Integra Biosciences Corporation has been awarded a firm fixed price purchase order valued at $24,989.97 by the National Institutes of Health, an agency of the Department of Health and Human Services, to provide products or services in support of NIH's biomedical research programs. The place of performance will be Bethesda, Maryland. The period of performance is one year, beginning September 15, 2023 and ending September 14, 2024. No additional details were provided regarding the scope of work...
- This is a $32,065.20 firm-fixed price purchase order awarded by the U.S. Environmental Protection Agency's Office of Research and Development to Integra Biosciences Corp., a foreign-owned manufacturer of laboratory equipment. The contract is for maintenance of six VIAFLO 96/384 liquid handling instruments at the company's facility in Hudson, New Hampshire. The contract has no set-aside designation and will run through December 31, 2025. Integra Biosciences is an established federal contractor,...
- This $31,950.90 firm-fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency of the U.S. government, to Integra Biosciences Corp., a foreign-owned for-profit manufacturer of laboratory equipment. The award is for Integra's proprietary VIAFLO pipetting system, which supports the agency's biomedical research and other scientific initiatives. While the contract has no set-aside designation, Integra has previously received small...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases has awarded a $25,843.22 firm fixed price delivery order contract to Integra Biosciences Corp., a foreign-owned for-profit manufacturer of laboratory equipment. The contract is for the provision of two VIAFLO 384 pipetting heads, to be delivered by July 31, 2023. This award is made under the Multiple Award Schedule (MAS) contract vehicle. Integra Biosciences Corp. has...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed-price purchase order to Integra Biosciences Corp. valued at $11,691.00 for administrative de-obligation of unexpended and expiring fiscal year 2021 funding. This action was conducted in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2026 closing of the period of availability for these fiscal year funds. The award, issued on May 4, 2021 with an ultimate completion date of June 4,...
- The Department of Health and Human Services' Food and Drug Administration awarded a $120,000 firm fixed price purchase order to Global Life Sciences Solutions USA LLC for a BIACORE 1K+ Upgrade Kit. The prime contractor, a subsidiary of Danaher Corporation, will provide the upgrade kit to support the FDA's work. Performance will take place in Marlborough, Massachusetts over approximately one year. No set aside designation or subcontractors were indicated. The award falls under HHS/FDA programs...
- This contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Environmental Health Sciences to Integra Biosciences Corp., a manufacturer of laboratory equipment and supplies. The $12,921.61 firm fixed-price purchase order provides Integra's liquid handling, media preparation, sterilization, and cell cultivation products to support biomedical research. The contract has no set-aside designation and runs through April 18, 2024....
- The U.S. Army Materiel Command awarded a $32,943.30 firm-fixed-price purchase order contract to Integra Biosciences Corp., a foreign-owned, for-profit manufacturer, for an automated liquid handling system. The contract was awarded on August 27, 2024 and has a completion date of October 1, 2024. The system will be delivered to a location in Hudson, New Hampshire. This sole-source contract was awarded under Solicitation W911QX24Q0199, which was not set aside for any small business category....
The Department of Health and Human Services Food and Drug Administration awarded a $25,000 purchase order to Integra Biosciences Corp. of Hudson, New Hampshire for a digital microfluidic platform. The firm fixed price contract runs from September 11, 2023 through October 17, 2023 and has a total small business set aside designation. Integra Biosciences will provide the FDA with equipment and services to support its regulatory review and approval processes for medical devices and other products within its purview. No major subcontractors were identified. The one month period of performance indicates this is likely a short-term requirement to augment the FDA's evaluation capabilities as it carries out its mission to protect public health.
Generated 12/22/23, 10:56 PM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.0k | 9/11/23 |